Keeping the Beat: Screening and Management of High-Risk Patients with Non-Valvular Atrial FibrillationPremiere Date: Wednesday, October 7, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, October 7, 2021
Note: Credit Is No Longer Available
|Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
|Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation
Cardiovascular Division, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
|Margot Savoy, MD, MPH, FAAFP, FABC, CPE, CMQ, FAAPL
Department of Family and Community Medicine
Lewis Katz School of Medicine at Temple University
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, projected to affect 12 million Americans by 2030. However, a significant number of AF cases, particularly non-valvular atrial fibrillation (NVAF) remain undiagnosed, putting patients at risk for severe cardiovascular (CV) complications, including increased risk of stroke. It is imperative that clinicians identify the symptomatology of AF and effectively diagnose NVAF, as these complications can potentially be avoided by increased screening and guideline-directed anticoagulation treatment. Unfortunately, despite the fact that both opportunistic and systematic screening have been shown to be effective in detecting NVAF, clinicians often lack knowledge of the available tools and strategies for implementing it, particularly in primary care settings.
This CME Outfitters Live and OnDemand webcast will feature expert faculty addressing the impact of undiagnosed NVAF, the benefit and use of screening tools for early detection, best practices for optimizing screening, implementing oral anticoagulant therapy for stroke prevention, and the use of digital health technologies, with a goal of fostering collaborative care and optimizing patient outcomes.
At the end of this CE activity, participants should be able to:
- Implement opportunistic and systematic screening in primary care settings to identify patients with NVAF who might benefit from anticoagulant therapy.
- Integrate current guidelines into the management of patients with NVAF.
- Incorporate the latest resources and strategies to facilitate collaborative care and optimize patient outcomes.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Explain how to identify patients with NVAF in the primary care setting who might benefit from anticoagulant therapy.
- Summarize current guidelines on the management of patients with NVAF.
- Discuss the latest resources and strategies for collaborative care and optimized patient outcomes.
Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.
Primary care physicians, cardiologists, nurse practitioners, PAs, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bhatt reports he is a consultant for Abbott; Afimmune; Amarin Corporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eisai Inc.; Ethicon USA, LLC; Ferring Pharmaceuticals: Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC.; Medtronic; PhaseBio Pharmaceuticals, Inc.; Pfizer Inc.; PLx Pharma Inc.; Regeneron; Roche; Sanofi-Aventis U.S. LLC; Synaptic Pharmaceutical Corp.; and The Medicines Company.
Dr. Cannon reports that he receives research grants from Amgen Inc.; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He is a consultant for Aegerion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals ,Inc.; Amarin Corporation; Amgen Inc.; Applied Therapeutics; Ascendia Pharmaceuticals; Boehringer-Inghelheim; Bristol-Myers Squibb Company; Corvidia; Eli Lilly and Company; HLS Therapeutics Inc.; Innocent Biologics, Inc.; Janssen Pharmaceuticals, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Pfizer Inc.; Rhoshan Pharmaceuticals, Inc.; and Sanofi-Aventis.
Dr. Savoy has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Rachel Speer, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).